SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
                         Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported): November 15, 2005

                         Saliva Diagnostic Systems, Inc.
                         -------------------------------
             (Exact name of Registrant as specified in its charter)

                                    Delaware
                                    --------
                 (State or other jurisdiction of incorporation)

      000-21284                                             91-1549305
  -----------------                                      ----------------
     (Commission                                         (IRS Employer
     File Number)                                      Identification No.)

    1 Clarks Hill Rd. Framingham, MA.                         01702
----------------------------------------                    ----------
(Address of principal executive offices)                    (Zip Code)

                                 (508) 872-2625
              ----------------------------------------------------
              (Registrant's telephone number, including area code)

                                 NOT APPLICABLE
          -------------------------------------------------------------
          (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))

--------------------------------------------------------------------------------
<PAGE>

ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
          APPOINTMENT OF PRINCIPAL OFFICERS.

On November 15, 2005, the Board of Directors of Saliva Diagnostic Systems, Inc.
(the "Board") elected D. Bruce Pattison, President and Chief Operating Officer
of the Company, and Richard Woodrich to serve as directors effective as of that
date. Mr. Pattison's business experience and terms of employment are reported in
the Company's Report on Form 8-K filed May 10, 2005, incorporated herein by
reference.

On the same date, the Board established a Board Audit Committee, appointing
current director Joseph Levi and Mr. Woodrich as its intial members, with Mr.
Woodrich as Chairman. Mr. Woodrrich has more than 17 years experience working in
senior executive positions in the biopharmaceutical industry. Mr. Woodrich
served as Senior Vice President, Business Development at Therion Biologics
Corporation from 1999 to 2004, as Chief Operating Officer of Cytomed, Inc. from
1996 to 1999, as President and Chief Operating Officer of Oculon Corporation
from 1992 to 1995, and as Chief Financial Officer of Applied Biotechnology from
1986 to 1991. Mr. Woodrich is a Certified Public Accountant and a graduate of
The Harvard Graduate School of Business Administration. He is a member of the
Massachusetts Biotechnology Council and the Biotechnology Industry Organization.
Mr. Woodrich will receive a fee of $40,000 per year for serving as Audit
Committee Chairman.

                                    Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

December 6, 2005                        SALIVA DIAGNOSTIC SYSTEMS, INC.


                                        By: s/s
                                            ------------------------------------
                                            Steve M. Peltzman
                                            Chairman Board of Directors
                                            Chief Executive Officer
{"company-data": {"conformed-name": "SALIVA DIAGNOSTIC SYSTEMS INC", "cik": "0000885534", "assigned-sic": "3841", "irs-number": "911549305", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-21284", "film-number": "051247940"}, "business-address": {"street1": "2294 NOSTRAND AVE.", "city": "BROOKLYN", "state": "NY", "zip": "11210", "phone": "7185523599"}, "mail-address": {"street1": "2294 NOSTRAND AVE.", "city": "BROOKLYN", "state": "NY", "zip": "11210"}}
SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
                         Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported): November 15, 2005

                         Saliva Diagnostic Systems, Inc.
                         -------------------------------
             (Exact name of Registrant as specified in its charter)

                                    Delaware
                                    --------
                 (State or other jurisdiction of incorporation)

      000-21284                                             91-1549305
  -----------------                                      ----------------
     (Commission                                         (IRS Employer
     File Number)                                      Identification No.)

    1 Clarks Hill Rd. Framingham, MA.                         01702
----------------------------------------                    ----------
(Address of principal executive offices)                    (Zip Code)

                                 (508) 872-2625
              ----------------------------------------------------
              (Registrant's telephone number, including area code)

                                 NOT APPLICABLE
          -------------------------------------------------------------
          (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))

--------------------------------------------------------------------------------
ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
          APPOINTMENT OF PRINCIPAL OFFICERS.

On November 15, 2005, the Board of Directors of Saliva Diagnostic Systems, Inc.
(the "Board") elected D. Bruce Pattison, President and Chief Operating Officer
of the Company, and Richard Woodrich to serve as directors effective as of that
date. Mr. Pattison's business experience and terms of employment are reported in
the Company's Report on Form 8-K filed May 10, 2005, incorporated herein by
reference.

On the same date, the Board established a Board Audit Committee, appointing
current director Joseph Levi and Mr. Woodrich as its intial members, with Mr.
Woodrich as Chairman. Mr. Woodrrich has more than 17 years experience working in
senior executive positions in the biopharmaceutical industry. Mr. Woodrich
served as Senior Vice President, Business Development at Therion Biologics
Corporation from 1999 to 2004, as Chief Operating Officer of Cytomed, Inc. from
1996 to 1999, as President and Chief Operating Officer of Oculon Corporation
from 1992 to 1995, and as Chief Financial Officer of Applied Biotechnology from
1986 to 1991. Mr. Woodrich is a Certified Public Accountant and a graduate of
The Harvard Graduate School of Business Administration. He is a member of the
Massachusetts Biotechnology Council and the Biotechnology Industry Organization.
Mr. Woodrich will receive a fee of $40,000 per year for serving as Audit
Committee Chairman.

                                    Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

December 6, 2005                        SALIVA DIAGNOSTIC SYSTEMS, INC.

                                        By: s/s
                                            ------------------------------------
                                            Steve M. Peltzman
                                            Chairman Board of Directors
                                            Chief Executive Officer